Encompass Health (NYSE:EHC) Given New $95.00 Price Target at Mizuho

Encompass Health (NYSE:EHC) had its target price increased by Mizuho from $93.00 to $95.00 in a research report report published on Thursday morning, Benzinga reports. The brokerage currently has a buy rating on the stock.

EHC has been the subject of several other research reports. Truist Financial increased their price objective on shares of Encompass Health from $82.00 to $86.00 and gave the stock a buy rating in a research report on Friday, February 9th. Stephens reissued an overweight rating and set a $85.00 price objective on shares of Encompass Health in a research report on Tuesday, January 16th. Barclays increased their price objective on shares of Encompass Health from $95.00 to $101.00 and gave the stock an overweight rating in a research report on Thursday, March 28th. Royal Bank of Canada reissued an outperform rating and set a $83.00 price objective on shares of Encompass Health in a research report on Friday, February 9th. Finally, William Blair reissued an outperform rating on shares of Encompass Health in a research report on Wednesday, February 7th. Eight equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, Encompass Health has a consensus rating of Buy and a consensus price target of $86.56.

Encompass Health Stock Down 0.3 %

Shares of NYSE:EHC opened at $82.47 on Thursday. Encompass Health has a 52 week low of $57.55 and a 52 week high of $85.84. The company has a debt-to-equity ratio of 1.14, a quick ratio of 1.28 and a current ratio of 1.37. The company has a market capitalization of $8.26 billion, a PE ratio of 22.29, a PEG ratio of 1.50 and a beta of 0.94. The company has a 50 day moving average price of $78.25 and a two-hundred day moving average price of $70.91.

Encompass Health (NYSE:EHC) last issued its earnings results on Wednesday, April 24th. The company reported $1.12 EPS for the quarter, beating the consensus estimate of $0.93 by $0.19. Encompass Health had a net margin of 7.60% and a return on equity of 18.01%. The firm had revenue of $1.32 billion during the quarter, compared to the consensus estimate of $1.27 billion. During the same quarter in the prior year, the firm earned $0.88 earnings per share. The business’s quarterly revenue was up 13.4% on a year-over-year basis. Analysts forecast that Encompass Health will post 4.1 earnings per share for the current year.

Encompass Health Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Monday, April 15th. Investors of record on Monday, April 1st were given a $0.15 dividend. This represents a $0.60 dividend on an annualized basis and a yield of 0.73%. The ex-dividend date of this dividend was Thursday, March 28th. Encompass Health’s dividend payout ratio (DPR) is currently 16.22%.

Institutional Trading of Encompass Health

Large investors have recently added to or reduced their stakes in the company. Principal Securities Inc. acquired a new stake in Encompass Health in the fourth quarter valued at $25,000. Benjamin F. Edwards & Company Inc. lifted its stake in Encompass Health by 360.2% in the fourth quarter. Benjamin F. Edwards & Company Inc. now owns 405 shares of the company’s stock valued at $27,000 after acquiring an additional 317 shares during the last quarter. McGlone Suttner Wealth Management Inc. acquired a new stake in Encompass Health in the fourth quarter valued at $30,000. GAMMA Investing LLC acquired a new stake in Encompass Health in the fourth quarter valued at $33,000. Finally, C M Bidwell & Associates Ltd. acquired a new stake in Encompass Health in the third quarter valued at $35,000. Institutional investors and hedge funds own 97.25% of the company’s stock.

Encompass Health Company Profile

Encompass Health Corporation provides post-acute healthcare services in the United States and Puerto Rico. It owns and operates inpatient rehabilitation hospitals that provide medical, nursing, therapy, and ancillary services. The company provides specialized rehabilitative treatment on an inpatient basis to patients who have experienced physical or cognitive disabilities or injuries due to medical conditions, such as strokes, hip fractures, and various debilitating neurological conditions.